Vitamin B12 Interactions: Drugs, Supplements and Food

1. Interaction Summary

Vitamin B12 interactions are situations in which a medication, nutrient, food component or health exposure changes how the body absorbs, transports or uses vitamin B12 (cobalamin), or changes how its status is measured. For most people the practical issue is that some commonly used medicines can, over time, lower B12 status. That effect is different from B12 changing how a drug works, which is rare and weakly documented.

B12 is unusual among vitamins because absorption is a multi-step process. Food-bound B12 is released by stomach acid and pepsin, binds to intrinsic factor (a protein made by the stomach), and is absorbed in the terminal ileum. A small fraction of a large oral dose is also absorbed by passive diffusion. The vitamin then travels bound to transport proteins, including transcobalamin, and serves as a cofactor for two enzymes: methionine synthase and methylmalonyl-CoA mutase. A factor that disrupts any step can matter.

The most clinically relevant findings, in brief:

• Metformin is associated with lower B12 concentrations and a higher risk of deficiency, with randomized-trial support.
• Acid-suppressing drugs (proton pump inhibitors and histamine-2 receptor antagonists) are associated with deficiency in observational studies, mainly with long-term use.
• Nitrous oxide inactivates B12 and can cause serious neurological harm, especially with repeated or heavy exposure or when B12 status is already low.
• Supplement and food effects are mostly about adequacy of intake and absorption capacity, not true blocking interactions.
• Laboratory effects can make a measured level misleading, even when the body's true status is unchanged.

The evidence differs greatly in strength across these items, and Section 9 explains how this article classifies it.

2. How Interactions Are Identified

Pharmacokinetic and pharmacodynamic interactions

A pharmacokinetic interaction changes the absorption, distribution, metabolism or excretion of a compound. Most B12-related interactions are of this kind: a drug alters stomach acid, gut function or transport, and B12 status falls. A pharmacodynamic interaction alters the biological effect itself. Nitrous oxide is the clearest example, because it chemically inactivates the cobalamin that enzymes need.

Types of evidence

Evidence comes from several sources, each with strengths and limits:

• Randomized controlled trials can show causation, but few are long enough to detect slowly developing deficiency.
• Observational studies (cohort and case-control) reveal associations in large populations but are open to confounding. For example, older adults on acid suppressants often have other risk factors for low B12.
• Case reports and series flag rare or severe events but cannot show how common they are.
• Mechanistic and laboratory research explains why an effect is plausible but does not prove it occurs in people.
• Authoritative guidance from bodies such as the NIH Office of Dietary Supplements and national haematology guidelines synthesizes these sources.

Factors that change risk

Dose, duration of exposure, baseline B12 stores, age, gastrointestinal health and diet all modify risk. The body holds relatively large B12 stores in the liver (often several years' worth), so deficiency tends to emerge slowly. Brief drug exposure in a well-nourished person rarely matters; prolonged exposure in an older person with marginal intake is a different situation. Supplement formulation (tablet, sublingual, injection) also affects how much B12 reaches tissues.

Interaction, adverse effect and deficiency: three different things

• An interaction is a documented change caused by combining two exposures.
• An adverse effect is a harmful outcome of a single exposure.
• Deficiency is a state of inadequate B12 that can have many causes, including pernicious anemia, low intake, malabsorption and drugs.

A person with low B12 who takes metformin does not necessarily have a drug-caused deficiency; the cause must be assessed clinically.

3. Vitamin B12 Drug Interactions: Drug Classes of Concern

This section reviews classes linked to B12 status, including metformin and Vitamin B12 and proton pump inhibitors and Vitamin B12. Not every drug in a class behaves identically, and most users never develop deficiency.

Metformin and other glucose-lowering treatments

• Proposed mechanism: Reduced calcium-dependent uptake of the B12-intrinsic factor complex in the ileum has been proposed; altered gut bacteria and motility are other candidates. The mechanism is not fully settled.
• Evidence: A randomized, placebo-controlled trial found lower B12 concentrations after metformin treatment (de Jager 2010). The Diabetes Prevention Program Outcomes Study reported that longer metformin exposure was associated with a higher risk of low B12 (Aroda 2016). Reviews describe a consistent association (Infante 2021).
• Consequences: Low B12 can overlap with diabetic neuropathy symptoms, which makes recognition harder.
• Risk factors: Longer duration and higher dose; other risk factors, such as age and concurrent acid suppression, may add to risk.
• Monitoring: Clinical guidance in several countries suggests considering periodic B12 assessment in long-term users, particularly those with anemia or neuropathy. Whether and how often to test is a clinician's decision.
• Other agents: Evidence for glucose-lowering drugs other than metformin is limited; this article does not extend the finding to the whole category.

Proton pump inhibitors and other acid-suppressing therapy

• Proposed mechanism: Stomach acid and pepsin free B12 from food proteins. Reduced acid lowers absorption of food-bound B12, whereas crystalline B12 in supplements and fortified foods does not depend on acid in the same way.
• Evidence: A large case-control study found that acid-suppressant use was associated with higher odds of a B12 deficiency diagnosis, with greater odds at higher doses and longer use (Lam 2013). Observational data cannot exclude confounding, and short-term use appears unlikely to cause problems in people with adequate stores.
• Histamine-2 receptor antagonists: The same study found an association for these drugs, generally weaker than for PPIs.
• Consequences and monitoring: Deficiency, if it occurs, develops over years. Some guidance suggests assessing B12 in long-term users who have other risk factors or symptoms.

Nitrous oxide

Nitrous oxide oxidizes the cobalt atom in cobalamin and inactivates methionine synthase (Sanders 2008). In people with normal stores, a brief anesthetic exposure is usually inconsequential. Repeated, prolonged or recreational use, or exposure in someone with unrecognized deficiency, has been linked to myeloneuropathy (spinal cord and nerve damage), with numbness, weakness and gait problems. This is the most clearly mechanistic and clinically serious interaction in this article. Anyone with known or suspected B12 deficiency should ensure the anesthesia team knows before nitrous oxide is considered.

Other medications and exposures

Several other medicines are listed in reference sources as being associated with reduced B12 absorption or status, including certain antibiotics, colchicine, some anticonvulsants and bile acid sequestrants (NIH ODS). Evidence for these is generally limited to small studies or case reports, and effects at ordinary doses are uncertain. Prior gastric or ileal surgery, and conditions such as Crohn disease or atrophic gastritis, are not drug interactions but are major independent causes of impaired absorption.

4. Specific Documented Interactions

The table below summarizes interactions discussed in the literature. Evidence labels follow the framework in Section 9.

Medication or exposure	Proposed mechanism	Evidence type	Potential clinical significance	Evidence strength
Metformin	Reduced ileal uptake of B12-intrinsic factor complex; possible gut-microbiome effects	Randomized trial, secondary analysis of large trial, cohort studies, reviews	Lower serum B12; deficiency risk rises with dose and duration; possible neuropathy or anemia	Well-supported
Proton pump inhibitors	Reduced acid-dependent release of food-bound B12	Case-control and cohort studies; guidance	Association with deficiency, mainly long-term and higher-dose use	Moderately supported
Histamine-2 receptor antagonists	Reduced gastric acid secretion	Case-control study; observational data	Smaller association than for PPIs	Moderately supported
Nitrous oxide	Oxidation of cobalamin; inhibition of methionine synthase	Mechanistic and toxicological research; case reports and series	Neurological injury with heavy or repeated use, or with low B12	Well-supported (mechanism and clinical reports)
Colchicine, certain antibiotics, anticonvulsants, bile acid sequestrants	Various proposed effects on absorption or metabolism	Small studies, case reports, reference-source listings	Uncertain at ordinary doses	Limited
Folate (high-dose)	Correction of anemia may mask underlying B12 deficiency	Clinical observation, cohort data	Delayed recognition of B12 deficiency; not a direct absorption interaction	Moderately supported

Notes on individual entries

Metformin. The strongest human evidence comes from a trial lasting several years in which B12 fell more in the metformin group than in the placebo group (de Jager 2010). Risk was higher with longer exposure in the Diabetes Prevention Program follow-up (Aroda 2016). The studies do not show that everyone on metformin becomes deficient; they show that the average level falls and the proportion with low values increases.

Acid suppressants. The best-known study is large but observational (Lam 2013). The association is credible and biologically plausible for food-bound B12, but the size of the effect for any individual is uncertain.

Nitrous oxide. Here the mechanism is established, and clinical consequences are documented chiefly through case reports and clinical series, which is expected given the ethics of studying harm prospectively.

Practical precautions supported by reliable sources: tell prescribers about all medicines and supplements, report new numbness, tingling, balance problems or unusual fatigue, and avoid recreational nitrous oxide use.

5. Theoretical and Mechanistic Interactions

A plausible mechanism is not the same as demonstrated harm. Several suggested interactions fall into this category:

• Gut microbiome changes from metformin or acid suppression might alter B12 production or competition in the intestine. Human data are preliminary.
• Cellular transport: Laboratory studies examine how drugs might affect cobalamin receptors or transport proteins; these findings have not been shown to produce clinical effects at therapeutic doses.
• Drug-induced changes in homocysteine or methylation pathways may reflect folate, B6 or B12 status, and distinguishing the contributions is difficult.
• Reports of B12 affecting drug action (for example, effects on chemotherapy or other drug metabolism) rest mainly on cell, animal or small human observations and should not be treated as clinical facts.

Limitations: small samples, short follow-up, surrogate outcomes such as serum levels instead of symptoms, and confounding by age and disease. Research gaps: long-term randomized trials of acid suppressants, whether supplementation prevents clinical (not just biochemical) outcomes in drug users, and the role of the microbiome.

6. Vitamin B12 Supplement Interactions

Folate and other B vitamins

Folate and B12 work together in one-carbon metabolism. High folate intake can correct the megaloblastic anemia of B12 deficiency without correcting its neurological effects, so a normal blood count may mask an underlying B12 problem. This is a clinical-recognition issue and not a case of folate blocking B12 absorption. Observational data from older U.S. adults suggest the relationship between folate and B12 status and cognitive or anemia outcomes is complex (Morris 2007). The finding does not justify avoiding folate; it supports checking B12 status in people who receive folic acid for anemia.

Combination products

Multivitamin and B-complex formulas can supply B12 conveniently along with related nutrients. A limitation is that fixed doses may not match individual needs, and people with malabsorption may need a different route. No convincing evidence shows that ordinary doses of other B vitamins deplete or block B12.

Other supplements

Evidence that vitamin C, calcium or iron at ordinary doses meaningfully affects B12 supplement absorption is limited or inconsistent, and such claims should be treated cautiously. Calcium is involved in the ileal uptake mechanism, which is why calcium status is sometimes discussed alongside metformin, but this does not establish that routine calcium supplements fix or cause B12 problems. High-dose supplementation should be guided by assessment, because multiple deficiencies often coexist and can look like an interaction.

7. Food Interactions

Absorption pathways

Food B12 is protein-bound and requires gastric acid and pepsin before binding intrinsic factor. In contrast, the crystalline B12 in supplements and fortified foods is already free, which is why people with low acid or atrophic gastritis often absorb it better than food-bound B12 (NIH ODS).

Meal timing

There is no strong evidence that taking oral B12 with or without food changes outcomes meaningfully for most people. Dose and regularity are more relevant than timing. Personal tolerance can guide the choice, and a pharmacist can advise on interactions with a person's specific medicines.

Dietary patterns

B12 occurs naturally almost only in animal-derived foods. Vegans and many vegetarians therefore depend on fortified foods or supplements, and studies report higher rates of low B12 in these groups, with variation across populations (Pawlak 2013). This is a matter of nutritional adequacy rather than a food-drug interaction. Older adults may also have reduced absorption of food-bound B12 because of lower acid production (Allen 2009).

What is not supported

There is no reliable evidence that ordinary foods interfere with B12 supplements. Alcohol misuse can impair nutrition and gut function and is a recognized risk factor for deficiency, but that reflects overall health and diet rather than a specific food-supplement clash.

8. Laboratory-Test Interference

Serum B12 is the usual first test but is imperfect: values near the lower range can be ambiguous, and levels may not reflect tissue status. Methylmalonic acid (MMA) and homocysteine rise when B12 function is inadequate and can help clarify borderline results; however, MMA can be elevated by kidney impairment and homocysteine by folate or B6 deficiency, among other factors. Holotranscobalamin is another marker used in some settings (Stabler 2013; Devalia 2014).

Supplement use before testing can raise serum B12 without proving prior adequacy, so clinicians usually ask about supplement use. Some immunoassay platforms rely on biotin chemistry, and the U.S. Food and Drug Administration has warned that high-dose biotin supplements can interfere with certain laboratory tests, with the affected assays varying by manufacturer. Anyone who takes high-dose biotin should tell the laboratory or clinician before blood is drawn. A laboratory artefact is distinct from a true change in B12 status, which is why results need interpretation by a qualified professional in the context of symptoms, diet, medicines and other test results. Readers should not diagnose deficiency or adjust treatment from a single number.

9. Severity and Strength of Evidence

The categories below are an explanatory framework created for this article. They are not a substitute for a formal, validated evidence-grading system such as GRADE.

• Well-supported: consistent clinical evidence and/or authoritative guidance supports a meaningful association or interaction.
• Moderately supported: human evidence suggests an association, but uncertainty remains.
• Limited evidence: findings are preliminary, inconsistent, or from small or observational studies.
• Theoretical: a plausible mechanism exists, but clinically meaningful effects are not established.

Criteria used: study design (randomized versus observational), consistency across studies, clinical relevance (symptoms versus laboratory values only), dose and duration findings, and population-specific risk.

Interaction	Quality and design	Consistency	Dose/duration	Key uncertainties
Metformin	Randomized trial plus cohorts	Consistent	Risk rises with time and dose	Clinical outcomes; optimal monitoring interval
Acid suppressants	Observational	Generally consistent	Higher with long-term, higher-dose use	Confounding; magnitude for individuals
Nitrous oxide	Mechanistic plus case reports	Consistent	Heavy or repeated use	Exact thresholds; role of baseline B12
Other drugs	Small studies, case reports	Inconsistent	Unclear	Whether effects are clinically relevant
Folate masking	Clinical observation	Consistent in principle	High folate intake	Frequency in practice

10. Who Should Consult a Clinician

Professional advice is appropriate for people who:

• take medications associated with reduced B12 status, particularly long-term;
• have confirmed or suspected B12 deficiency;
• have gastrointestinal conditions or past gastrointestinal surgery that may affect absorption;
• have symptoms that might fit deficiency, such as numbness, tingling, weakness, balance problems, memory change or unusual fatigue;
• use many medicines and supplements;
• are pregnant or breastfeeding and have concerns about nutrient adequacy or medicines;
• are considering high-dose supplements or any change to prescribed treatment.

Do not stop prescribed medication or replace treatment with supplements without professional guidance.

Seek prompt medical assessment for new or progressive neurological symptoms (for example, worsening numbness, difficulty walking, weakness or confusion), because delay can allow nerve damage to become permanent.

11. Frequently Asked Questions

1. What medications can interfere with Vitamin B12 absorption? Metformin and acid-suppressing drugs have the best evidence. Nitrous oxide inactivates B12. Other medicines are listed with weaker evidence.

2. Does metformin affect Vitamin B12 levels? On average, yes: a randomized trial and large follow-up studies show lower B12 with longer use. Not everyone develops deficiency.

3. Can proton pump inhibitors reduce Vitamin B12 absorption? They can reduce absorption of food-bound B12, and observational studies link long-term use with deficiency. Short-term use is less concerning.

4. Can acid-reducing medications affect Vitamin B12 status? Possibly. Associations exist for both PPIs and H2 blockers, with uncertainty about individual risk.

5. Does Vitamin B12 interact with other vitamins? The main interaction is clinical: high-dose folate can mask B12-deficiency anemia. Ordinary doses of other vitamins are not shown to block B12.

6. Can Vitamin B12 be taken with folate? They are often combined in formulations. Because folate can hide a B12 problem, clinicians consider B12 status when treating anemia.

7. Do foods interfere with Vitamin B12 supplements? There is no reliable evidence that ordinary foods do.

8. Is it better to take Vitamin B12 with food or on an empty stomach? Evidence does not show a meaningful difference for most people; consistency and tolerance matter more.

9. Can Vitamin B12 supplements affect laboratory test results? Yes. Supplements raise serum B12, and high-dose biotin can interfere with some immunoassays. Tell the clinician about all supplements before testing.

10. Can Vitamin B12 interact with prescription medications? Most documented interactions involve drugs lowering B12 status. Direct effects of B12 on drug action are rarely documented. A pharmacist can check specific combinations.

11. Who is at greater risk of medication-associated Vitamin B12 deficiency? Older adults, long-term or high-dose users, people with low dietary intake (including vegans), and those with gastrointestinal disease or surgery.

12. Should Vitamin B12 be monitored when taking certain medications? Some guidance supports considering it in long-term metformin users or those with symptoms or other risks. A clinician decides.

13. Can Vitamin B12 supplementation replace a medication review? No. A review identifies causes, while supplements address only the vitamin.

14. When should someone seek medical advice about a possible interaction? When taking relevant medicines long-term, when symptoms appear, or before major supplement or medication changes. Seek prompt care for new or worsening neurological symptoms.

12. Scientific References

These references were selected from well-known published sources. Before publication, each citation, DOI and link should be re-verified against PubMed or the publisher, since this draft could not live-check them. Where a DOI is not listed, none was confirmed.

1. National Institutes of Health, Office of Dietary Supplements. (updated periodically). Vitamin B12: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
2. de Jager J, Kooy A, Lehert P, et al. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 340:c2181. doi:10.1136/bmj.c2181
3. Aroda VR, Edelstein SL, Goldberg RB, et al. (2016). Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism, 101(4):1754-1761. doi:10.1210/jc.2015-3754
4. Infante M, Leoni M, Caprio M, Fabbri A. (2021). Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World Journal of Diabetes, 12(7):916-931. doi:10.4239/wjd.v12.i7.916
5. Lam JR, Schneider JL, Zhao W, Corley DA. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22):2435-2442. doi:10.1001/jama.2013.280490
6. Sanders RD, Weimann J, Maze M. (2008). Biological effects of nitrous oxide: a mechanistic and toxicological review. Anesthesiology, 109(4):707-722. doi:10.1097/ALN.0b013e3181870a17
7. Stabler SP. (2013). Vitamin B12 deficiency. New England Journal of Medicine, 368:149-160. doi:10.1056/NEJMcp1113996
8. Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. (2014). Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British Journal of Haematology, 166(4):496-513. doi:10.1111/bjh.12959
9. Morris MS, Jacques PF, Rosenberg IH, Selhub J. (2007). Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. American Journal of Clinical Nutrition, 85(1):193-200. doi:10.1093/ajcn/85.1.193
10. Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. (2013). How prevalent is vitamin B12 deficiency among vegetarians? Nutrition Reviews, 71(2):110-117. doi:10.1111/nure.12001
11. Allen LH. (2009). How common is vitamin B-12 deficiency? American Journal of Clinical Nutrition, 89(2):693S-696S.
12. U.S. Food and Drug Administration. Safety communications on biotin interference with laboratory tests (2017, updated 2019). Available on FDA.gov; confirm the current page before citing.
13. Metformin and acid-suppressant prescribing information. U.S. FDA-approved labeling via DailyMed (dailymed.nlm.nih.gov); cite the specific product label consulted.

Limitations and gaps: Most acid-suppressant data are observational; long-term randomized trials with clinical endpoints are lacking; evidence for secondary drug classes is thin; and biomarker interpretation varies by laboratory and population.

Final evidence update date: October 14, 2026.